Lorazepam

Quick links to important sections

Lorazepam

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lorazepam

Property Description
Active Ingredient Lorazepam (INN)
Form Tablet, Oral Solution, Injection
Pharmacological Class Benzodiazepine derivative
General Purpose Anxiolytic and Sedative-Hypnotic
Origin Synthetic Compound

What Type of Medicine is Lorazepam?

Lorazepam is a synthetic, single-ingredient psychotropic medication that belongs to the benzodiazepine derivative pharmacological class. Its active substance is the molecule Lorazepam (INN), which is chemically defined by its structure as 7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one. Functionally, the drug is categorized as both an anxiolytic and a sedative-hypnotic. This categorization relates to its use in managing acute states of pathological anxiety or tension. Within its class, Lorazepam is characterized as an intermediate-acting agent.

Composition, Form, and General Purpose

The pharmaceutical preparation of Lorazepam is notably comprehensive, available for both oral and parenteral routes of administration. These forms include the solid tablet, the liquid oral solution, and the sterile injection suitable for intramuscular or intravenous use. As a single-ingredient product, its composition involves the active Lorazepam molecule combined with either solid excipients or an aqueous solution vehicle. The general therapeutic purpose of Lorazepam is to provide swift calmness and sedation by acting as a Central Nervous System (CNS) depressant. This effect is utilized for controlling severe agitation and convulsions, reflecting the medicine's role in stabilizing the body and mind during periods of extreme tension or heightened neuronal activity.

Regulatory References

  1. Lorazepam in WHO Essential Medicines List

What side effects are possible with Lorazepam?

Possible side effects and safety information

The official safety profile of Lorazepam is largely defined by its Central Nervous System (CNS) depressant activity, which accounts for the most frequently documented adverse reactions. These effects are classified according to regulatory frequency standards.

Frequency-Classified Adverse Reactions

Classification Examples of Officially Listed Adverse Reactions
Very Common Sedation, Drowsiness.
Common Ataxia (unsteadiness), Dizziness, Fatigue, Muscle Weakness.
Less Common Confusion, Hypotension, Transient Anterograde Amnesia, Paradoxical Reactions (e.g., agitation, rage).

Adverse effects are documented across various System-Organ Classes, including Nervous System Disorders, Psychiatric Disorders, Respiratory Disorders, and Hepatobiliary Disorders.

Serious Safety Risks and Limitations

Regulatory documents highlight the risk of developing physical dependence and subsequent acute, life-threatening withdrawal reactions, including seizures, following abrupt discontinuation. This risk is officially noted to increase with higher doses and longer treatment duration.

The FDA includes a mandatory warning regarding the risk of profound sedation, respiratory depression, coma, and death when Lorazepam is used concurrently with opioids. Other significant limitations include Contraindications in patients with known hypersensitivity to benzodiazepines and those with acute narrow-angle glaucoma.

Population-Specific Considerations

Elderly or Debilitated Patients are officially noted to be more susceptible to the drug's sedative effects, which increases the risk of falls. Caution is also required in patients with severe hepatic insufficiency due to the potential to worsen hepatic encephalopathy.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Lorazepam is primarily characterized by a progression of Central Nervous System (CNS) Depression. Officially documented presentations start with somnolence, confusion, ataxia (loss of coordination), and slurred speech, potentially advancing to stupor and coma (Source 1.1, 2.2).

Life-threatening outcomes that require urgent intervention include respiratory depression and hypotension (low blood pressure), especially when Lorazepam is combined with other CNS depressants like opioids, which significantly increases the risk of death (Source 1.4, 1.5).

In case of suspected overdose, regulatory documents mandate that you seek immediate medical attention or call emergency services (e.g., 911) immediately (Source 1.4, 2.1). This action is required if symptoms include difficulty breathing, an inability to wake, or collapse.

Supportive Care and Antidote

Supportive care is the principal management approach, focused on maintaining the airway and monitoring vital signs (Source 4.4). The specific benzodiazepine antagonist, Flumazenil, may be used to reverse effects, but its use carries a documented regulatory warning due to the risk of precipitating acute withdrawal reactions, including seizures (Source 1.5, 3.4).

Therapeutic Uses of Lorazepam

What Lorazepam Treats: Main Uses and Benefits

Lorazepam is commonly used to help with the short-term relief of symptoms related to severe anxiety and excessive tension. The medication is applied across domains where additional symptomatic support is needed to address symptom clusters like overwhelming worry, acute fear, and restlessness. This supportive use contributes to easing the overall symptom load during difficult episodes.

The medication plays a role in managing symptoms of increased neurological activity in contexts involving acute neurological crises, such as continuous convulsive seizures (Status Epilepticus) and severe agitation associated with alcohol withdrawal syndrome. It is relevant in clinical settings for rapid intervention when symptoms escalate temporarily.

Lorazepam is also used as a premedication to reduce apprehension before surgical or invasive procedures. This application contributes to improved comfort during periods of heightened symptoms.

“This application supports general well-being during acute crises and highly stressful clinical scenarios.”

Indications often covered include: Severe anxiety, anxiety-related insomnia, Status Epilepticus, acute agitation, and pre-procedure anxiety.


Quick Fact: Support for Acute Tension
Symptom Domain: Excessive mental and physical tension.
Core Benefit: Contributes to easing the overall symptom load.

Eligibility and Restrictions for Use

Who Can and Cannot Use Lorazepam? (Official Eligibility)

Eligibility for Lorazepam use is strictly defined by regulatory documents, focusing on patient populations, pre-existing conditions, and life stages where use is prohibited or restricted.

Absolute Non-Eligibility (Contraindications)

Condition/Population Restriction Type
Known Hypersensitivity Prohibited
Acute Narrow-Angle Glaucoma Prohibited

Restricted or Not-Recommended Use

Age and Development

  • Children Under 12: Safety and effectiveness are not established for oral tablets; use is generally restricted.
  • Elderly Patients: Requires caution and close monitoring due to increased sensitivity to sedative effects and higher risk of falls.

Comorbid Conditions

  • Severe Hepatic Insufficiency: Use requires caution as it may worsen hepatic encephalopathy.
  • Compromised Respiratory Function (e.g., severe COPD, sleep apnea): Use requires caution due to the risk of respiratory depression.
  • Myasthenia Gravis: Contraindicated or requires significant caution in certain formulations/jurisdictions.

Pregnancy and Lactation

  • Pregnancy: Use is generally not recommended, especially in the late phase, due to potential risks (e.g., neonatal withdrawal syndrome).
  • Breastfeeding: Lorazepam is excreted into milk; use is not recommended or requires specific risk-benefit assessment.

What should I know about interactions with other medicines?

Lorazepam Interactions with other medicines and products

Lorazepam's official interaction profile focuses on severe additive effects with central nervous system (CNS) depressants and pharmacokinetic changes due to enzyme inhibition.

Interaction Classifications (High-Level)

Classification Interacting Substance(s) Regulatory Outcome
Pharmacodynamic Enhancement Opioids, Alcohol, and other CNS Depressants (e.g., Antipsychotics, Barbiturates) Risk of profound sedation, respiratory depression, coma, and death.
Pharmacokinetic Alteration Valproate (Valproic Acid) or Probenecid Increased plasma concentrations and reduced clearance of lorazepam.

Official Interaction Statements

  • Co-administration with opioids carries a Boxed Warning regarding the risk of potentially fatal respiratory depression due to additive effects.
  • Co-use with alcohol results in enhanced CNS depressant effects, which increases the risk of severe sedation and respiratory issues.
  • Specific agents such as Clozapine co-administration have been associated with marked sedation, hypotension, and respiratory arrest.
  • Valproate and Probenecid inhibit the glucuronidation pathway that metabolizes lorazepam. The regulatory constraint requires that the lorazepam dose be reduced by approximately 50% when either of these agents is co-administered to account for the reduced clearance.
  • Theophylline or Aminophylline are documented to potentially reduce the sedative effects of lorazepam.
  • Elderly and debilitated patients may be more susceptible to the sedative effects when lorazepam is co-administered with other CNS depressants.

Mechanism of Action

Lorazepam functions as a positive allosteric modulator of the GABA A receptor, a ligand-gated chloride ion channel predominantly localized within the central nervous system (CNS). The GABA A receptor is a pentameric protein complex, and Lorazepam binds to a specific allosteric site located at the interface of the alpha and gamma subunits, distinct from the binding site of the primary endogenous neurotransmitter, gamma-aminobutyric acid ( GABA). This interaction with the receptor constitutes a modulatory type of interaction, not direct agonism. Binding of Lorazepam induces a conformational change in the receptor complex, which increases the affinity of GABA for its orthosteric binding site. The consequence of this enhanced affinity is an increase in the frequency of the chloride channel opening events, not the duration. The increased frequency of opening facilitates a greater influx of negatively charged chloride ions ( Cl^-) across the neuronal cell membrane. This transmembrane ion flux results in hyperpolarization of the postsynaptic neuron, causing the membrane potential to become more negative and thus moving it further away from its firing threshold. The resulting downstream cascade is a substantial reduction in neuronal excitability and overall inhibition of neurotransmission throughout the central nervous system.

Dosage and Administration Information

How to Use Lorazepam: Administration Guidelines

Lorazepam usage involves specific routes, standard dosing, and administration conditions. Lorazepam is intended for short-term use only, and its effectiveness for prolonged periods (e.g., greater than four months) has not been systematically assessed.

Administration Routes and Forms

Lorazepam is administered via three routes:

  • Oral: Available as tablets (0.5 mg, 1 mg, 2 mg), an oral concentrate (2 mg/mL), and extended-release (ER) capsules.
  • Intramuscular (IM): Used for injection.
  • Intravenous (IV): Used for injection, often in acute clinical settings.

Standard Dosing and Frequency

Dosing regimens depend on the context of use, with instructions for divided doses for daily use and single, acute doses for intervention.

Context Typical Adult Regimen Frequency/Timing Maximum Dose
Anxiety (Oral) 2 to 6 mg per day Divided doses (2–3 times daily) 10 mg/day
Insomnia (Oral) 2 to 4 mg Single dose at bedtime 4 mg/day
Status Epilepticus (IV) 4 mg, slow injection May repeat once after 10–15 minutes 8 mg total

Special Instructions and Patient Groups

Preparation and dosing adjustments are utilized to ensure proper use:

  • Older Adults: The initial oral dose is generally lower, typically starting at 1 to 2 mg per day in divided doses, with lower doses also applied for IV use.
  • Preparation: IV injection requires dilution with an equal volume of a compatible solution (e.g., normal saline) immediately before use. Oral concentrate must also be diluted before intake.
  • ER Capsules: These must be swallowed whole; they are not to be crushed or chewed.
  • Discontinuation: Due to the risk of withdrawal phenomena, treatment is withdrawn gradually rather than stopped abruptly.

Recent Clinical Evidence

Lorazepam: Recent Clinical Evidence

The clinical evidence for lorazepam is derived from formal research studies, including Randomized Controlled Trials (RCTs) and systematic scientific reviews, which are evaluated and documented by health authorities worldwide. This research explores whether symptoms changed across its studied uses.


Evidence for Short-Term Evaluation in Anxiety and Tension

The evidence for severe anxiety and tension has primarily involved short-term studies where adult participants were enrolled in RCTs to receive either lorazepam or a neutral comparator (placebo). These trials were designed to explore whether symptoms changed during the study period when lorazepam was administered. Researchers monitored validated anxiety rating scales to measure changes in symptom intensity or variability.

A key limitation of the evidence base is related to study duration. The core research exploring short-term symptom changes does not include systematic clinical studies designed to assess effects beyond a period of approximately four months. Therefore, long-term effects are not fully established, and there is limited information for evaluation lasting many months or years.


Research in Acute Crisis Settings

Research focused on rapid, acute episodes, such as continuous convulsive seizures, referred to as Status Epilepticus, where injectable lorazepam was studied. Studies in this area often involved comparison trials against another active treatment. Outcomes related to systemic or functional imbalance were evaluated, particularly the cessation of convulsive activity within defined time limits.

Research in pediatric patients reported that rate measurements of achieving seizure control in the lorazepam group were similar to those in the standard active comparator group. Additionally, reports described that differences in measured sedation between the lorazepam cohort and the active comparator were observed in some acute care trials. The nature of this research means that follow-up durations were limited to the acute and immediate post-crisis phase.


What Remains Uncertain in the Research Landscape

Overall, the certainty remains low regarding sustained outcomes, as the long-term effects are not fully established by randomized trials. The most significant research limitation is the lack of evidence detailing the clinical course and functional status of patients evaluated for longer than four months. Data for certain groups remain insufficient, particularly concerning the oral evaluation in younger children for anxiety.

Frequently Asked Questions (FAQ)

Common questions about Lorazepam (FAQ)

Q: How quickly does Lorazepam start working for anxiety?

A: According to official regulatory sources, Lorazepam is rapidly absorbed following oral intake, with the highest concentration in the blood typically reached within approximately two hours. For acute clinical situations, the intravenous (IV) form works much faster, with effects usually observed within one to three minutes.

Q: Is Lorazepam considered addictive?

A: Yes, official regulatory documents indicate that Lorazepam has the potential to cause physical dependence. Due to its potential for abuse and dependence, it is classified as a Schedule IV controlled substance by the US Drug Enforcement Administration (DEA).

Q: Does Lorazepam cause grogginess or fatigue the next day?

A: The drug has a terminal half-life of about 14 hours. This indicates that the drug can remain in the system for an extended period, which may result in residual effects such as drowsiness and fatigue that could potentially last into the next day.

Q: Can Lorazepam be taken with over-the-counter pain relievers like Tylenol or ibuprofen?

A: The official product information does not specifically list interactions with common over-the-counter pain relievers such as acetaminophen or ibuprofen. However, warnings are issued for severe additive effects when taken with other Central Nervous System (CNS) depressants.

Q: Does Lorazepam affect memory?

A: Yes, transient anterograde amnesia, which is temporary forgetfulness or difficulty forming new memories, is listed as a less common adverse reaction in official safety documents. This is a documented effect of Lorazepam.

Q: Does Lorazepam interact with common supplements like melatonin or St. John's Wort?

A: Official drug interaction statements primarily warn against specific prescription medicines and alcohol. Interactions with dietary or herbal supplements, such as St. John's Wort or melatonin, are not explicitly cited in the product information.

Q: What are the withdrawal symptoms associated with stopping Lorazepam?

A: If stopped abruptly after prolonged use, Lorazepam can lead to severe acute withdrawal reactions. These symptoms may include seizures, tremors, sweating, vomiting, and abdominal cramps, according to regulatory warnings.

Q: Does taking Lorazepam affect your reaction time for driving or operating machinery?

A: Yes, official warnings caution patients against operating hazardous machinery or driving a motor vehicle. As a CNS depressant, Lorazepam can impair the physical and mental abilities required for these tasks.

Q: Is it possible to develop a tolerance to Lorazepam over time?

A: Official warnings note that the risk of physical dependence increases with longer treatment duration. This indicates that the body may adapt to the presence of the drug, suggesting a potential for tolerance to develop.

Q: Can people with kidney disease take Lorazepam?

A: Studies referenced in regulatory documents indicate that in patients with impaired kidney function, the elimination half-life of Lorazepam and its metabolite may be increased. Therefore, caution is generally required, particularly with frequent dosing.

Q: Are there any documented cases of Lorazepam causing paradoxical reactions (like increased anxiety)?

A: Yes, regulatory listings of adverse reactions include reports of paradoxical reactions. These are instances where the drug causes the opposite of its intended effect, such as agitation, excitation, increased hostility, and rage, although these are considered less common.

Q: Does Lorazepam interact with common antidepressant medications (SSRIs)?

A: The official label issues broad warnings for co-administration with other Central Nervous System (CNS) depressants. While specific antidepressant classes like SSRIs are not always explicitly named, the full official drug label should be referenced for all documented interactions.

Q: Is Lorazepam safe to take during pregnancy?

A: Official guidance states that Lorazepam is generally not recommended during pregnancy, especially during the later stages. This is due to potential risks to the fetus, including the possibility of neonatal withdrawal syndrome.

Q: Will Lorazepam show up on a standard drug test?

A: As a member of the benzodiazepine class, Lorazepam may be detectable in standard drug screenings. The exact presence and detection time depend on the specific test and the drug’s elimination rate from the body.

Q: Do you need to take Lorazepam every day for anxiety or only as needed?

A: Regulatory documents list dosing regimens for different types of use. The label describes both daily, divided-dose regimens for the management of anxiety and single-dose regimens for specific, acute interventions.

Q: What is the half-life of Lorazepam?

A: According to official pharmacokinetic data, the terminal half-life of Lorazepam after injection averages 14 pm 5 hours. This measurement describes the rate at which the drug is eliminated from the system.

Q: What should you avoid eating or drinking while on Lorazepam?

A: Official warnings note a serious risk of enhanced Central Nervous System depressant effects when Lorazepam is used with alcohol. No other specific foods or non-alcoholic drinks are cited as contraindications on the label.

Q: Does Lorazepam make you feel 'out of it' or less emotional?

A: As a CNS depressant, Lorazepam can cause common side effects such as sedation, dizziness, and confusion. These effects may result in a general reduction in alertness, cognitive function, and emotional responsiveness.

Q: Why is it recommended to taper off Lorazepam instead of stopping abruptly?

A: Official guidance emphasizes that treatment should be withdrawn gradually because stopping abruptly carries a significant risk. This method helps to prevent acute, potentially life-threatening withdrawal reactions, including seizures.

Q: Is Lorazepam used for insomnia that is related to anxiety?

A: Yes, Lorazepam is officially indicated for the management of anxiety disorders and the short-term relief of anxiety or anxiety associated with depressive symptoms. This use also extends to treating insomnia that is due to anxiety or transient situational stress.

Q: How soon after taking Lorazepam can I breastfeed?

A: Regulatory information confirms that Lorazepam is excreted into breast milk. Official information indicates that a choice must be made regarding whether to continue the medication or to continue nursing, balancing the potential risks and benefits.

Q: Can people with a history of substance abuse safely be prescribed Lorazepam?

A: Official warnings state that patients with a history of drug or alcohol abuse require close monitoring. This is due to the known potential for abuse and dependence associated with Lorazepam.

Q: Why is Lorazepam listed as a controlled substance?

A: Lorazepam is classified as a Schedule IV controlled substance under US federal law. This classification is given because the drug has accepted medical uses but carries a defined, lower potential for abuse and risk of dependence relative to drugs in Schedule III.

Q: Do certain foods affect the absorption of Lorazepam?

A: The official label does not note any specific food interactions that impact the absorption of the oral tablet. However, the oral concentrate formulation must be diluted with a liquid (water, juice, soda) or a soft food (applesauce, pudding) prior to intake.

Q: Is Lorazepam effective for panic attacks?

A: Lorazepam is officially indicated for the management of anxiety disorders and the short-term relief of anxiety. This scope encompasses the treatment of severe anxiety and tension, which includes the acute symptoms commonly experienced during a panic attack.

Q: What research supports the use of Lorazepam for social anxiety?

A: The drug is indicated for the broad management of anxiety disorders. Studies described in official documents focus on generalized anxiety and tension and do not typically differentiate efficacy for specific anxiety subtypes, such as social anxiety.

Q: Is it possible for Lorazepam to cause skin rashes or allergic reactions?

A: Yes, Lorazepam is formally contraindicated in anyone with a known hypersensitivity (allergic reaction) to benzodiazepines. Adverse reactions like skin rashes have also been reported in official post-marketing surveillance data.

Q: Why is Lorazepam available in both tablet and liquid forms?

A: The official drug information lists the availability of tablets, an oral solution (liquid concentrate), and an injection. These different dosage forms are necessary to provide flexibility for various clinical settings and administration routes.

How should Lorazepam be stored and disposed of?

How to Store and Dispose of Lorazepam

Lorazepam must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F), with permitted excursions up to 30 C. The medication must be kept in its original container, which should be tightly closed, and protected from light and moisture.

Child Safety and Disposal

To prevent accidental access, Lorazepam must be stored securely and out of the reach of children and pets, often requiring a locked cabinet. Unused or expired Lorazepam must be disposed of properly. Regulatory bodies recommend utilizing an available drug take-back program. Disposal via flushing or household trash is not generally recommended.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lorazepam found in:

A-Z Index: